Rius Medical

The Business Plan “red blood cells for drug delivery” depicts an investment opportunity with strong return on Investment at year 3. For early investors’ review of Rius Medical, here in the Business Plan you have all information provided to investors interested in forming a syndicate. 

Gaining traction in cell therapy is gene engineering. You see that in CAR-T /CAR-NK cell therapies with viral vectors addition of CAR genes. And you can see that also with iPS derived cell therapies like Bayer acquisition of BlueRock Therapeutics ¹. Rius Medical takes advantage of that and goes THREE steps further. (1) Yes we add genes for cell therapies. (2) Furthermore, what is unique in our approach is that we are the only company using a “master template” that significantly reduce Industry Challenges relative to our competitors e.g. Erytech Pharma or Rubius Therapeutics. (3) The three of us combine (Rius Medical, Erytech Pharma and Rubius Therapeutics) have the same product - red blood cells for drug delivery. What makes Rius Medical unique is that our gene engineering approach brings the only solution to Industry Challenges (i.e. enables market entry with strong profit earnings). Despite successful phase III clinical data ² with acute lymphoblastic leukemia, Erytech Pharma discontinued it’s Leukaemia program in June 2018 ³ and instead shifted focus to solid tumor, now under phase III clinical studies in pancreatic cancer. 

Simply having a higher price tag is not attracting customers. Market approved CAR-T cells by Novartis and Gilead Sciences illustrate that ⁴. It is working - proof of concept is established in engineering stem cells and there are thousands of research scientists around the world doing the same thing I did in stem cells research, i.e. culture stem cells into cellular therapies that work under academia settings! Those that were able to get financing are demonstrating that in clinical studies (again Erytech Pharma and Rubius Therapeutics). Nonetheless Industry Challenges ⁵ are a problem we as scientists face in developing cell therapies. That’s why I left academia to start Rius Medical that offers a solution to the Industry Challenges. The business opportunity here with FIVE assets, brings 54 million euro Return on Investment to investors at year 3 on up to 1 million euro equity capital investment. 

It would be helpful to know how early investors wish to move forward. After all, there is no innovation without collaboration! Are you against forming a syndicate of investors?

Many thanks and warmest regards, 

Denis Demarais